Contrasting BIOFRONTERA AG/ADR (NASDAQ:BFRA) & Endo International (NASDAQ:ENDP)

BIOFRONTERA AG/ADR (NASDAQ:BFRA) and Endo International (NASDAQ:ENDP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Profitability

This table compares BIOFRONTERA AG/ADR and Endo International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BIOFRONTERA AG/ADR 4.48% 6.82% 2.35%
Endo International -16.89% -99.08% 5.58%

Risk & Volatility

BIOFRONTERA AG/ADR has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Endo International has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BIOFRONTERA AG/ADR and Endo International, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BIOFRONTERA AG/ADR 0 1 1 0 2.50
Endo International 2 9 2 0 2.00

BIOFRONTERA AG/ADR currently has a consensus target price of $11.00, indicating a potential downside of 3.08%. Endo International has a consensus target price of $7.42, indicating a potential upside of 71.29%. Given Endo International’s higher probable upside, analysts plainly believe Endo International is more favorable than BIOFRONTERA AG/ADR.

Institutional & Insider Ownership

0.0% of BIOFRONTERA AG/ADR shares are held by institutional investors. Comparatively, 95.2% of Endo International shares are held by institutional investors. 1.5% of Endo International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares BIOFRONTERA AG/ADR and Endo International’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BIOFRONTERA AG/ADR $24.93 million 10.16 -$10.48 million N/A N/A
Endo International $2.95 billion 0.33 -$1.03 billion $2.89 1.50

BIOFRONTERA AG/ADR has higher earnings, but lower revenue than Endo International.

Summary

Endo International beats BIOFRONTERA AG/ADR on 7 of the 13 factors compared between the two stocks.

BIOFRONTERA AG/ADR Company Profile

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products. In addition, it is developing Ameluz for the treatment of basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. The company offers its products primarily in the United States and Europe. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The U.S. Branded Pharmaceuticals segment provides XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's diseases; SUPPRELIN LA for central precocious puberty treatment; TESTOPEL, a long-acting implantable pellet for the treatment of central precocious puberty; NASCOBAL, a nasal spray to treat vitamin B12 deficiency; and AVEED for the treatment of hypogonadism. This segment also offers pain management products, such as PERCOCET, VOLTAREN Gel, and LIDODERM; TESTIM Gel for the treatment of endogenous testosterone; and FORTESTA Gel for hypogonadism treatment. The International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Receive News & Ratings for BIOFRONTERA AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOFRONTERA AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.